GLP Watchdog

Compounding Pharmacy · Largo, FL · 503B

BPI Labs Review

Largo, Florida. Belcher Pharmaceuticals owns it, and FDA registers it both as a drug manufacturer and as a 503B outsourcing facility. Injectable semaglutide and tirzepatide were made here at scale for telehealth brands, and Belle Health's own pharmacy list still names it as the maker of its tirzepatide. FDA has since moved to strike both molecules from the 503B bulk-drug list.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

503BFDA-registered 503B outsourcing facilityFDA-registered drug manufacturer
Location: Largo, FL
Website: Official site
States licensed: no list on file
6.0
★★★☆☆6.0/10

Our own score · methodology

Telehealth Brands That Fill Through This Pharmacy

Each seller below names BPI Labs as a pharmacy that compounds or fills its prescriptions, in its own site, terms or filings. We keep the page and the date we read it. Arrangements like these are commercial, and they get changed without announcement.

Belle Health charges one monthly price at every dose.

7.9/ 10
Verified partner

Belle Health

Best for: flat-rate compounded GLP-1s with weekly dietitian check-ins included

★★★★☆7.9/10

Editorial score · methodology

$199/mo
CompoundedSemaglutideTirzepatideBPC-157MOTS-cLegitScript Verified
Get StartedRead full Belle Health review →

Accreditations and Standards

Sterile compounding in this country runs on one rulebook, General Chapter <797> of the United States Pharmacopeia[4]. Depending on what is being made, the finished preparation is then tested for sterility under USP <71>[5] and for bacterial endotoxins under USP <85>[6]. Every pharmacy on this page owes those standards already. Which regulator oversees the pharmacy depends on its route, set out in our explainer on 503A and 503B compounding pharmacies. What follows is what this one has added on top.

FDA-registered 503B outsourcing facility
The facility appears on the FDA's own register as a 503B outsourcing facility. That listing brings it inside the FDA's inspection remit and holds it to cGMP.
FDA-registered drug manufacturer
A further credential the pharmacy discloses about itself.

What It Compounds

Whether any pharmacy may compound semaglutide or tirzepatide at all turns on where the reference product sits on the FDA Drug Shortage List. When a drug comes off that list the door closes, and it has closed before[7].

Semaglutide
Compounds semaglutide
Tirzepatide
Compounds tirzepatide

States Licensed

BPI Labs publishes no state-by-state licensure list, so we cannot tell you whether it is licensed where you live. Put that question to your own state board of pharmacy before you fill anything here.

What Regulators Have on File

2026-04
Voluntarily ceased compounded semaglutide and tirzepatide production amid the FDA's move to exclude GLP-1s from the 503B bulks list.
2026-04-17
FDA inspection of the Largo outsourcing facility; FDA's Registered Outsourcing Facilities list (updated 10/29/2026) records a Form 483 as issued and the action as 'Open'.

How GLP Watchdog Scored This Pharmacy

Accreditation held6/10
Standing with regulators5/10
States licensed0/10
GLP-1 compounding10/10
Years operating5/10

We research every score ourselves. The methodology page sets out how each part is weighted. To check any pharmacy yourself, follow the six public checks in our guide to verifying an online GLP-1 pharmacy, or run its name through the pharmacy legitimacy lookup.

High confidence · Last verified · How we check provider data

Frequently Asked Questions

Here is what we can and cannot confirm. BPI Labs operates as a 503B compounding pharmacy out of Largo, FL. Its record lists FDA-registered 503B outsourcing facility and FDA-registered drug manufacturer on top of its state board of pharmacy license. Our records carry 2 documented regulatory action(s), listed further down this page.
BPI Labs works out of Largo, FL. We have not recorded its state license list, which is not the same as it holding none — confirm shipping to your state with the pharmacy or your state board.
Alongside its other compounded preparations, BPI Labs makes compounded semaglutide and compounded tirzepatide. Being a 503B pharmacy, it may run sterile batches to FDA cGMP standards without waiting on a named patient. FDA says outsourcing facilities may not compound semaglutide or tirzepatide from bulk now that both shortages are over, so ask the facility on what basis it supplies them today.
Two things separate them: who inspects, and how much may be made at once. A 503B outsourcing facility registers with the FDA itself, works to current Good Manufacturing Practices (cGMP), submits to FDA inspection, and may make compounded medication in batches with no named patient attached. A 503A pharmacy cannot do that. It fills a prescription written for one patient, answers mainly to its state board of pharmacy, and works to the USP <797> standard for sterile compounding. Neither route produces an FDA-approved drug.

Glossary

The words sellers use, defined. Tap any term.

Where to fill semaglutideBack to the register
Sources & methodology — as of November 2026
  1. 1.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  2. 2.FDA — 503B Outsourcing Facility Registration and Requirements— U.S. Food & Drug Administration.
  3. 3.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
  4. 4.USP General Chapter <797> — Pharmaceutical Compounding: Sterile Preparations— United States Pharmacopeia.
  5. 5.USP General Chapter <71> — Sterility Tests— United States Pharmacopeia.
  6. 6.USP General Chapter <85> — Bacterial Endotoxins Test— United States Pharmacopeia.
  7. 7.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.